Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer’s Disease Patients
Identifieur interne : 002C40 ( Main/Exploration ); précédent : 002C39; suivant : 002C41Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer’s Disease Patients
Auteurs : Nathan Herrmann [Canada] ; Krista L. Lanctôt [Canada] ; Goran Eryavec [Canada] ; Lyla R. Khan [Canada]Source :
- Journal of Psychopharmacology [ 0269-8811 ] ; 2004-06.
Abstract
Loss of noradrenergic (NE) neurones in the locus ceruleus and compensatory changes in NE activity have been described in Alzheimer’s disease (AD), but have never been linked to treatment. The hypothesis of this study was that central NE responsivity would predict aggression response to treatment with a NE medication, pindolol. Fifteen institutionalized AD subjects [Mini-Mental State Examination (MMSE), mean 3.3 ± 4.6] with significant behavioural disturbances (Neuropsychiatric Inventory Score, mean 30.6 ± 14.6) were studied. Growth hormone (GH) response to clonidine challenge (5 μg/kg) was used as a measure of central NE responsivity. Subjects were then randomized to 7 weeks of treatment with pindolol, maximum dose 20 mg b.i.d., or an identical placebo capsule in a cross-over design. The primary outcome measure was change on the retrospective Overt Aggression Scale (r-OAS). Five of 11 completers (45%) had decreased total r-OAS scores. There was significant improvement noted on the r-OAS verbal aggression subscale (paired t = -2.5, p = 0.03) compared to placebo, but not r-OAS total. Higher baseline aggression, higher MMSE and lower GH response predicted improvement in aggression, accounting for 82% of the variance (r = 0.91, F = 10.5, p = 0.006). Changes in NE responsivity, as reflected by a blunted GH response to clonidine challenge and more severe aggression, were associated with better response to the NE agent pindolol. Individual patient characteristics, including underlying neurotransmitter changes, may be useful for predicting response to therapy.
Url:
DOI: 10.1177/0269881104042625
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001704
- to stream Istex, to step Curation: 001704
- to stream Istex, to step Checkpoint: 000D57
- to stream Main, to step Merge: 003001
- to stream Main, to step Curation: 002C40
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer’s Disease Patients</title><author wicri:is="90%"><name sortKey="Herrmann, Nathan" sort="Herrmann, Nathan" uniqKey="Herrmann N" first="Nathan" last="Herrmann">Nathan Herrmann</name></author><author wicri:is="90%"><name sortKey="Lanctot, Krista L" sort="Lanctot, Krista L" uniqKey="Lanctot K" first="Krista L." last="Lanctôt">Krista L. Lanctôt</name></author><author wicri:is="90%"><name sortKey="Eryavec, Goran" sort="Eryavec, Goran" uniqKey="Eryavec G" first="Goran" last="Eryavec">Goran Eryavec</name></author><author wicri:is="90%"><name sortKey="Khan, Lyla R" sort="Khan, Lyla R" uniqKey="Khan L" first="Lyla R." last="Khan">Lyla R. Khan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:791DC44A14721B55E2E5D97BA192411EF47E68B9</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1177/0269881104042625</idno><idno type="url">https://api-v5.istex.fr/document/791DC44A14721B55E2E5D97BA192411EF47E68B9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001704</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001704</idno><idno type="wicri:Area/Istex/Curation">001704</idno><idno type="wicri:Area/Istex/Checkpoint">000D57</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D57</idno><idno type="wicri:doubleKey">0269-8811:2004:Herrmann N:noradrenergic:activity:is</idno><idno type="wicri:Area/Main/Merge">003001</idno><idno type="wicri:Area/Main/Curation">002C40</idno><idno type="wicri:Area/Main/Exploration">002C40</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer’s Disease Patients</title><author wicri:is="90%"><name sortKey="Herrmann, Nathan" sort="Herrmann, Nathan" uniqKey="Herrmann N" first="Nathan" last="Herrmann">Nathan Herrmann</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author><author wicri:is="90%"><name sortKey="Lanctot, Krista L" sort="Lanctot, Krista L" uniqKey="Lanctot K" first="Krista L." last="Lanctôt">Krista L. Lanctôt</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, Sunnybrook and Women’s College Health Sciences Centre and Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author wicri:is="90%"><name sortKey="Eryavec, Goran" sort="Eryavec, Goran" uniqKey="Eryavec G" first="Goran" last="Eryavec">Goran Eryavec</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, North York General Hospital and University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author wicri:is="90%"><name sortKey="Khan, Lyla R" sort="Khan, Lyla R" uniqKey="Khan L" first="Lyla R." last="Khan">Lyla R. Khan</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Psychopharmacology</title><idno type="ISSN">0269-8811</idno><idno type="eISSN">1461-7285</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage CA: Thousand Oaks, CA</pubPlace><date type="published" when="2004-06">2004-06</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="215">215</biblScope><biblScope unit="page" to="220">220</biblScope></imprint><idno type="ISSN">0269-8811</idno></series><idno type="istex">791DC44A14721B55E2E5D97BA192411EF47E68B9</idno><idno type="DOI">10.1177/0269881104042625</idno><idno type="ArticleID">10.1177_0269881104042625</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-8811</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Loss of noradrenergic (NE) neurones in the locus ceruleus and compensatory changes in NE activity have been described in Alzheimer’s disease (AD), but have never been linked to treatment. The hypothesis of this study was that central NE responsivity would predict aggression response to treatment with a NE medication, pindolol. Fifteen institutionalized AD subjects [Mini-Mental State Examination (MMSE), mean 3.3 ± 4.6] with significant behavioural disturbances (Neuropsychiatric Inventory Score, mean 30.6 ± 14.6) were studied. Growth hormone (GH) response to clonidine challenge (5 μg/kg) was used as a measure of central NE responsivity. Subjects were then randomized to 7 weeks of treatment with pindolol, maximum dose 20 mg b.i.d., or an identical placebo capsule in a cross-over design. The primary outcome measure was change on the retrospective Overt Aggression Scale (r-OAS). Five of 11 completers (45%) had decreased total r-OAS scores. There was significant improvement noted on the r-OAS verbal aggression subscale (paired t = -2.5, p = 0.03) compared to placebo, but not r-OAS total. Higher baseline aggression, higher MMSE and lower GH response predicted improvement in aggression, accounting for 82% of the variance (r = 0.91, F = 10.5, p = 0.006). Changes in NE responsivity, as reflected by a blunted GH response to clonidine challenge and more severe aggression, were associated with better response to the NE agent pindolol. Individual patient characteristics, including underlying neurotransmitter changes, may be useful for predicting response to therapy.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Herrmann, Nathan" sort="Herrmann, Nathan" uniqKey="Herrmann N" first="Nathan" last="Herrmann">Nathan Herrmann</name></noRegion><name sortKey="Eryavec, Goran" sort="Eryavec, Goran" uniqKey="Eryavec G" first="Goran" last="Eryavec">Goran Eryavec</name><name sortKey="Khan, Lyla R" sort="Khan, Lyla R" uniqKey="Khan L" first="Lyla R." last="Khan">Lyla R. Khan</name><name sortKey="Lanctot, Krista L" sort="Lanctot, Krista L" uniqKey="Lanctot K" first="Krista L." last="Lanctôt">Krista L. Lanctôt</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:791DC44A14721B55E2E5D97BA192411EF47E68B9
|texte= Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer’s Disease Patients
}}
| This area was generated with Dilib version V0.6.29. |  |